Original Source(s)
Related Content
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
First MCT8 deficiency therapy approved
Clinical studies showed reductions in circulating thyroid hormone levels and changes in heart rate and systolic blood pressure.
September 29, 2026
-
3 min
